Piramal Pharma Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Amit Soni as an Independent Director. The company announced the formal voting process through a regulatory filing under Regulation 30 of SEBI Listing Regulations.

Postal Ballot Details

Director Appointment Proposal

The Board has approved the appointment of Mr. Amit Soni (DIN: 05111144) as a Non-Executive Independent Director for a five-year term. The appointment requires shareholder approval through a special resolution as mandated under SEBI Listing Regulations.

About Amit Soni

Mr. Soni brings extensive investment experience to Piramal Pharma's board. As a Partner at CVC Capital, he established the firm's India operations and has led significant investments across multiple sectors.

Professional Background

Educational Qualifications

Voting Process

The company will conduct voting exclusively through remote e-voting, with no physical ballot forms being distributed. Members whose email addresses are registered with the company or depositories will receive the notice electronically. The postal ballot notice includes detailed instructions for accessing the NSDL e-voting platform.

Current Directorships

Mr. Soni currently serves on the boards of several companies including Cohizon Life Sciences Limited, CVC Advisers (India) Private Limited, and Irelia Sports India Private Limited. He also holds committee positions in statutory committees of these organizations.

The appointment aligns with the company's commitment to strengthening its board composition with experienced professionals who can contribute to strategic decision-making and corporate governance.

Piramal Pharma has achieved a significant regulatory milestone for its bioconjugates manufacturing facility in Grangemouth, UK. The facility has received updated Good Manufacturing Practice (GMP) certificates from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), reinforcing its compliance with current manufacturing standards.

Key Highlights

• Facility Location: Grangemouth, UK
• Regulatory Body: UK's Medicines and Healthcare products Regulatory Agency (MHRA)
• Certification: Updated Good Manufacturing Practice (GMP) certificates
• Significance: Ensures compliance with current manufacturing standards

Impact on Operations

The updated GMP certification is crucial for Piramal Pharma as it:

1. Supports the company's pharmaceutical operations
2. Ensures compliance with regulatory requirements
3. Validates the facility's adherence to high-quality manufacturing practices

This regulatory approval underscores Piramal Pharma's commitment to maintaining stringent quality standards in its bioconjugates manufacturing processes. The certification may potentially enhance the company's position in the pharmaceutical industry, particularly in the specialized field of bioconjugates.

For stakeholders and partners, this update provides assurance of Piramal Pharma's continued dedication to quality and regulatory compliance in its UK operations.